Obermatt

PharmaEssentia

TAI:6446 · TW0006446008
BiotechnologyMedium

360

62
EV / EBIT32
Price / Owner Earnings5
Owner Earnings Yield69
Dividend Yield83
Price/Sales8
EV / Gross Profit34
Price/Book7
Return on Capital86
Cash Return on Capital78
Return on Equity78
EBIT Margin88
Gross Profitability74
Cash Conversion31
Accruals37
Owner Earnings Margin78
Sales growth93
Profit Growth92
Long-Term EPS Growth31
Owner Earnings Growth54
Reinvestment90
Price momentum92
Debt load84
Refinancing20
Debt Payback100
Liquidity92
Analyst ratings46
Opinion Changes11
Price Target Upside1
Market mood100
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

PharmaEssentia generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryTaiwan
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeTWSE
Employees278
ISINTW0006446008
Last UpdateApr 2, 2026
Themes
HematologyImmunologyInfectious DiseasesOncologyBiotechnologyHealth CareScience and Engineering

Description

PharmaEssentia Corporation, a pharmaceutical company, primarily focusing on the research and development of innovative medicine solutions. The company specializes in developing therapies for various diseases, with a significant emphasis on advancing…

Analysis

Middle-of-the-road

PharmaEssentia Corporation is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 89.6× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 20/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

What to watch: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
91
2026

All-time high

96

Mar 2026

All-time low

91

Jun 2026

Average rank

94

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
8
Price/Earnings
9
Price/Book
7
Dividend Yield
83
Value (overall)
15

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare PharmaEssentia with its peers
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
PharmGen Science
KSC:004720
74
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Samil Pharmaceutical
KSC:000520
28
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Myung In Pharm
KSC:317450
78
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Pyridam Farma
JKT:PYFA
3
CountrySingapore
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →